Objective To investigate the trend of breast cancer treatment and prognosis in 30 years. Methods Total 1 092 patients with breast cancer treated in the Peking Union Medical College Hospital between 1975 and 2006 were reviewed in six time phases for therapy, metastasis, and survival rate. Six time phases were 1975-1980 years, 1985-1986 years, 1990-1991 years, 1995-1996 years, 2000-2001 years and 2005-2006 years. Results Radical operation was the major treatment (68.9%， 91/132) of breast cancer in 1975-1980 and then became less popular until it was totally abandoned after 2001. The number of modified radical operation begun to rise from 1980 and reached its peak in 1995-1996 (94.9%， 146/154). The number of lumpectomy had been increasing since 2000, and that of chemotherapy had been rising since 1985-1986. But there was no apparent change of the percentage of radiotherapy treatment. In 1975-1980, only 0.8% （1/126） patients received endocrine therapy, but in 1990-1991, the ratio was 66.0% （33/50）. The metastasis and recurrence ratio was declining gradually in the 6 time phases (P＜0.05). The 5-year and 10-year disease free survival rates in the groups of 1990-1991, 1995-1996, 2000-2001, and 2005-2006 were apparently higher than those in two earlier groups of 1975-1980 and 1985-1986 (P＜0.05). Conclusion The conclusions of laboratory experiments and clinical trials on breast cancer are critical for improving prognosis.
Objective To investigate the effects of the nerve, endocrine, and immune factors on the process of wound healing and regeneration of the skin after injury and to review the research work in the past years in this area. Methods The prospective study was made to explore the relationship among the nerve, endocrine, immune factors, and skin tissue repair and regeneration, and to summarize the recent advance in this area. Results The nerve, endocrine, and immune factors played an important role in the repair and generation of the skin after injury. Conclusion As there has been fewer studies made in this field, we should reinforce the related basic research in this field.
Purpose To investigate the relationship between mitochondrial DNA 11778 mutation and clinical characteristics of patients with Laber is hereditary optic neuropathy(LHON). Methods PCR RFLPs (MaeⅢ) and mutation specific primer PCR(MSP-PCR) were used simultaneously to detect mitochondrial DNA 11778 mutation. Results Among 10 subjects who habored 11778 mutation,one was a carrier and nine were patients with LHON.Of the nine patients,six were males and three were females.The age of onset ranged from 12 to 25 years old and the onset interval of the two eyed varied between 0 to 6 months. The visual acuity was CF/10cm-0.1 except one who lost her vision after delivery but recovered gradually.The results of visual field,VEP and color vision were abnormal but ERG and systemic status were all normal. Conclusion Molecular biological detection of the ten subjects showed that they all habored mtDNA 11778 mutation.The existence of carrier and visual recovery imlied that mtDNA mutation was a primary cause of LHON,but other factors such as endocrine disorder might influence the pathogenesis of LHON. (Chin J Ocul Fundus Dis,1998,14:156-158)
Radionuclides can be labeled on biomolecules with specific binding ability. By binding with specific targets of tumors, particles such as α or β emitted by the radionuclides will specifically irradiate tumors and produce ionizing radiation effects, resulting in cell senescence and death within the irradiation range, achieving tumor treatment results, and this way has little impact on surrounding normal tissues. Lutetium-177 (177Lu) can emit γ rays for CT imaging, and can also emit β rays for tumor treatment, so 177Lu is now one of the radionuclides that can be used for integrated diagnosis and treatment. This review summarizes the clinical application of 177Lu in several solid tumors, in conjunction with currently published research.
Objective To summarize the application and advancement of liver transplantation for hepatic metastasis from neuroendocrine tumor. Methods Domestic and overseas publications on the study of liver transplantation for hepatic metastasis from neuroendocrine tumor in recent years were collected and reviewed. Results Liver transplantation can offer good relief of symptoms, long disease-free intervals, and potential cure in individual patients with hepatic metastatic tumor. Important selection criteria are well-differentiated tumors and a low proliferation rate (Ki67＜10%). Conclusion In carefully selected patients with metastatic neuroendocrine tumors, liver transplantation is an appropriate option.
Endocrinology is closely related to lipid metabolism. Lipotoxicity affects the abnormal function of various endocrine organs, and leads to diabetes, fatty liver, metabolic syndrome and other endocrine and metabolic diseases. It is an important strategy to prevent the lipid toxicity. Endocrine disorders can also cause dyslipidemia. Studies have found that thyroid and gonadal glands play an important role in lipid metabolism. Their molecular mechanisms are gradually revealed and will be a new therapeutic target for dyslipidemia. Lipid metabolism disorders play an important role in the development of endocrine and metabolic diseases.
【摘要】 目的 探讨老年性乳腺癌术前内分泌治疗效果及降期后手术优点。 方法 2004年5月－2010年12月19例老年性局部晚期乳腺癌患者，术前给予口服芳香化酶抑制剂（aromatase inhibitors，AI）2～10个月，进行疗效观察，降期后手术及术后同一有效内分泌药物继续治疗并随访，时间1～66个月。 结果 自AI治疗开始至手术时，临床完全缓解2例，部分缓解11例，稳定3例，进展3例；手术14例，另5例由于全身状况差、基础疾病严重不能耐受手术或局部进展而放弃手术，5年总生存率68%，无瘤生存率47%。 结论 术前内分泌治疗疗效可靠，不良反应轻，特别适应老年伴有内科疾病不适应化学疗法的患者，可以增加保乳手术率和手术切除率。【Abstract】 Objective To investigate the clinical value of neo-adjuvant endocrine therapy for locally advanced breast cancer in elderly patients and the advantages of operation after down-staging of breast cancer. Methods From May 2004 to December 2010, 19 patients with locally advanced breast cancer were treated with Aromatase inhibitor (AI) neo-adjuvant endocrine therapy for 2 to 10 months before operation. The clinical efficacy was observed. Operation was performed after down-staging of the cancer. After the operation, patients continued taking the same effective drug and were followed-up for 1 to 66 months. Results From AI treatment to the time of operation, there were 2 cases of clinical complete response, 11 cases of clinical partial response, 3 cases of stable disease, and 3 cases of progressive disease. A total of 14 patients were operated, and 5 other patients could not have the operation for bad body conditions, serious basic-diseases or local progress of the disease. The 5-year overall survival rate was 68%, and the disease-free survival rate was 47%. Conclusion Neo-adjuvant endocrine therapy has a reliable clinical effect and low side-effects. It is especially suitable for elderly patients excluded from chemotherapy because of internal medical diseases. It can also increase the rate of breast-conserving and surgical excision.